Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617393 | 1.00 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL382338 | 1.00 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL11034837 | 0.88 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL25531048 | 0.87 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL15011935 | 0.86 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL4101161 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL359650 | 0.82 | ALDH1A1 (0.65) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL29134391 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1CTSL | |
| Cyclobutylcarbamic Acid Benzyl Ester SCHEMBL332814 | 0.81 | EPHX1 (0.76) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL17207725 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023108031-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| CN-105294531-A | Synthetic method of kainic acid | UNIV SHAANXI NORMAL | 2016-02-03 | — | — | CN | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2005117543-A2 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| CN-1054980-A | Optically active 8-BAY 128039 carboxylic acid derivative, their preparation method and their intermediate | KYORIN SEIYAKU KK (JP) | 1991-10-02 | — | — | CN | disclosed |
| EP-0415487-A2 | Beta-lactams as anticholesterolemic agents | MERCK & CO. INC. (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | ALDH1A1 3731/4885GAA 2001/4885TSHR 4124/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885GAA 3831/4885TSHR 3295/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | ALDH1A1 3430/4885GAA 4757/4885TSHR 299/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | ALDH1A1 3731/4885GAA 2001/4885TSHR 4124/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | ALDH1A1 3731/4885GAA 2001/4885TSHR 4124/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | ALDH1A1 4016/4885GAA 2370/4885TSHR 4317/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | ALDH1A1 2354/4885GAA 2829/4885TSHR 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.